This content is in French.
Myocardial infarction: a single-dose drug to support heart repair
17 mars 2026
By Elodie Vaz | Published on March 17, 2026 | 3 min readMyocardial infarction is one of the leading causes of cardiovascular mortality and disability worldwide. Even when patients survive the acute event, the consequences for the heart can be long-lasting. The blockage of a coronary artery deprives tissue of oxygen, leading to the death of part of the heart muscle. In the weeks that follow, the he
By Elodie Vaz | Published on March 17, 2026 | 3 min read
Myocardial infarction is one of the leading causes of cardiovascular mortality and disability worldwide. Even when patients survive the acute event, the consequences for the heart can be long-lasting. The blockage of a coronary artery deprives tissue of oxygen, leading to the death of part of the heart muscle. In the weeks that follow, the heart attempts to repair itself, but this healing phase often results in the formation of fibrotic tissue, which is less functional than healthy cardiac muscle.
Myocardial infarction is one of the leading causes of cardiovascular mortality and disability worldwide. Even when patients survive the acute event, the consequences for the heart can be long-lasting. The blockage of a coronary artery deprives tissue of oxygen, leading to the death of part of the heart muscle. In the weeks that follow, the heart attempts to repair itself, but this healing phase often results in the formation of fibrotic tissue, which is less functional than healthy cardiac muscle.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Zhang K, Tao H, Zhu D, Yue Z, Hu S, Wu Y, et al. Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction. Science. 2026 Mar 5;391(6789):eadu9394.
View the source
